FDA Cracks Eggs Over Safety Regs: Comment by April!
Published Date: 3/13/2026
Notice
Summary
The FDA is updating how it collects info about egg safety rules to keep food safe and healthy. This affects state and local food safety teams who help protect us from foodborne illnesses. They’re asking for your thoughts by April 13, 2026, to make sure the process is smooth and effective—no big cost changes expected!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
State and Tribal Reporting Burden Estimates
FDA estimates reporting burden per submission at 569 hours. For ERPS submissions FDA estimates 2 respondents, 1 response each, totaling 1,138 reporting hours; for AFRPS submissions FDA estimates 25 respondents, 1 response each, totaling 14,225 reporting hours; combined reporting burden is 15,363 hours. FDA also estimates annual recordkeeping burden totaling 11,800 hours (ERPS recordkeeping 800 hours; AFRPS recordkeeping 11,000 hours) and states there are no capital or operating and maintenance costs associated with this collection.
Revised Egg Safety Program Standards
The FDA revised the Egg Regulatory Program Standards (ERPS) to reflect lessons learned from the 2021 ERPS and updated program definitions, all 10 program standards, appendices, and assessment worksheets. States that have adopted ERPS will use the revised worksheets and forms, perform a baseline self-assessment in the first year of enrollment, and submit comprehensive reviews in subsequent years to verify conformance and improve program effectiveness and clarity.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-04939 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mammography Standards Quality Act Requirements
The FDA is asking for public feedback on renewing rules that keep mammogram centers safe and reliable. These rules affect mammography facilities, making sure their equipment, staff, and practices meet high standards. Comments are due by April 13, 2026, and this process helps protect patients without adding extra costs.
Next: 2026-04941 — 2026 Environmental Financial Advisory Board (EFAB) Federal Advisory Committee Act (FACA) Charter 2-Year Renewal
The EPA is renewing the Environmental Financial Advisory Board (EFAB) for two more years to keep getting smart ideas on how to fund environmental and public health projects without spending extra taxpayer money. This board helps the EPA find ways to save money and attract private investments. The renewal keeps the board active through 2028 with a budget of about $287,000 per year.